Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Stefan O. Ciurea, Piyanuch Kongtim, Ankur Varma, Gabriela Rondon, Julianne Chen, Samer Srour, Qaiser Bashir, Amin Alousi, Rohtesh Mehta, Betul Oran, Uday Popat, Chitra Hosing, Amanda Olson, Naval Daver, Marina Konopleva, Richard E. Champlin

Blood (2020) 135 (6): 449–452.

https://doi.org/10.1182/blood.2019003662

Published: 2020

Includes: Supplemental data

Journal Articles

High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Michael Wayne Henderson, MSc, Erica Sparkenbaugh, PhD BS, Denis Noubouossie, MD PhD, Reiner Mailer, Thomas Renne, MD PhD, Keith R McCrae, MD, Nigel S. Key, MBChB, FRCP, Rafal Pawlinski, PhD

Blood (2019) 134 (Supplement_1): 3621.

https://doi.org/10.1182/blood-2019-127206

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

Trephine Immuno-Histochemistry As an Useful Adjunct in Characterizing Myelonecrosis in Resource Poor Settings - a Study from India

Shruti Mishra, MBBS, MD PDF Hematology, Somanath Padhi, MBBS MD, Rasheeda Mohamedali, MBBS, Kishore Kumar, MBBS, MD DM

Blood (2019) 134 (Supplement_1): 5028.

https://doi.org/10.1182/blood-2019-128772

Published: 2019

Journal Articles

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Mayken Visser, Rene van Oerle, Hugo ten Cate, MD PhD, Volker Laux, PhD, Stefan Heitmeier, PhD, Henri M.H. Spronk, PhD

Blood (2019) 134 (Supplement_1): 1106.

https://doi.org/10.1182/blood-2019-131738

Published: 2019

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Neda Alrawashdh, Nimer Alkhatib, Ali McBride, PharmD, MS, Daniel Persky, MD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2018-99-112619

Published: 2018

Journal Articles

Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors

Priyanka Pophali, MD, Melissa C. Larson, MS, Cristine Allmer, BS, Umar Farooq, MD, Brian K. Link, MD, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2018) 132 (Supplement 1): 4791.

https://doi.org/10.1182/blood-2018-99-117822

Published: 2018

Journal Articles

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 3400.

https://doi.org/10.1182/blood.V130.Suppl_1.3400.3400

Published: 2017

Journal Articles

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Eytan M. Stein, MD, Jipan Xie, MD PhD, Emilie Duchesneau, Subrata Bhattacharyya, PhD, Briana Ndife, MPH, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2017) 130 (Supplement 1): 4703.

https://doi.org/10.1182/blood.V130.Suppl_1.4703.4703

Published: 2017

Journal Articles

Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 4711.

https://doi.org/10.1182/blood.V130.Suppl_1.4711.4711

Published: 2017

Journal Articles

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, Mok Oh, Daniel Persky, MD, Faiz Anwer, MD, Leslie Andritsos, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4678.

https://doi.org/10.1182/blood.V130.Suppl_1.4678.4678

Published: 2017

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, HyunJung Kim, Mok Oh, Leslie Andritsos, MD, Faiz Anwer, MD, Daniel Persky, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4679.

https://doi.org/10.1182/blood.V130.Suppl_1.4679.4679

Published: 2017

Journal Articles

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

Ahmed Aljabri, Yvonne Huckleberry, Jason H. Karnes, Mahdi Gharaibeh, Hussam I. Kutbi, Yuval Raz, Seongseok Yun, Ivo Abraham, Brian Erstad

Blood (2016) 128 (26): 3043–3051.

https://doi.org/10.1182/blood-2016-07-728030

Published: 2016

Journal Articles

Androgen Receptor Overexpression in Mantle Cell Lymphoma: Potential Novel Therapeutic Implications

Paul S Martin, MD, Elahe Mostaghel, MD PhD, Stephen Mongovin, Shani L. Frayo, Ailin Zhang, Kerstin Lara Edlefsen, MD, Oliver W Press, MD PhD, Ajay K. Gopal, MD

Blood (2016) 128 (22): 3014.

https://doi.org/10.1182/blood.V128.22.3014.3014

Published: 2016

Journal Articles

Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

Veronika Ehrlich, Peter Leidenmuehler, Barbara Dietrich, Gerald Hoebarth, Tanja Ruthsatz, Peter L. Turecek, PhD, Martin Wolfsegger, Cstat (RSS), Alfred Weber, Herbert Gritsch, Werner Hoellriegl, Marietta Turecek

Blood (2016) 128 (22): 4977.

https://doi.org/10.1182/blood.V128.22.4977.4977

Published: 2016

Journal Articles

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

Ronan T. Swords, MDPhDFRCPI FRCPath, Shaun Brothers, PhD, Nagi Ayad, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Ana Rodriguez, Shawn Johnstone, PhD, Jeffrey Albert, Joseph Collard, Arthur Zelent, PhD, Claes Wahlestedt, PhD

Blood (2015) 126 (23): 2552.

https://doi.org/10.1182/blood.V126.23.2552.2552

Published: 2015

Journal Articles

Cost-Effectiveness Evaluation for the US of Fondaparinux Compared to Argatroban in the Management of Suspected HIT

Ahmed Aljabri, Pharm.D., Mahdi Gharaibeh, MSc., Yvonne Huckleberry, Pharm.D., Hussam Kutbi, Pharm.D., Yuval Raz, MD, Seongseok Yun, MD PhD, Ivo Abraham, PhD, Brian Erstad, Pharm.D.

Blood (2015) 126 (23): 4727.

https://doi.org/10.1182/blood.V126.23.4727.4727

Published: 2015

Journal Articles

Cost-Effectiveness of Subtype-Based Treatment Strategies for Diffuse Large B-Cell Lymphoma Patients (DLBCL)

Ashley D. Staton, MD, Qiushi Chen, Turgay Ayer, PhD, Daniel Goldstein, MD, Jean L. Koff, MD, Christopher R. Flowers, MD

Blood (2015) 126 (23): 4476.

https://doi.org/10.1182/blood.V126.23.4476.4476

Published: 2015

Journal Articles

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Peter L. Turecek, PhD, Juergen Siekmann, PhD, Artur Mitterer, PhD, Michael Graninger, PhD, Gerald Schrenk, PhD, Peter Matthiessen, PhD, Hanspeter Rottensteiner, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD

Blood (2015) 126 (23): 3536.

https://doi.org/10.1182/blood.V126.23.3536.3536

Published: 2015

NARROW

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Trephine Immuno-Histochemistry As an Useful Adjunct in Characterizing Myelonecrosis in Resource Poor Settings - a Study from India

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

Androgen Receptor Overexpression in Mantle Cell Lymphoma: Potential Novel Therapeutic Implications

Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

Cost-Effectiveness Evaluation for the US of Fondaparinux Compared to Argatroban in the Management of Suspected HIT

Cost-Effectiveness of Subtype-Based Treatment Strategies for Diffuse Large B-Cell Lymphoma Patients (DLBCL)

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only